Advertisement

Advertisement
Issues in Oncology

FDA Perspective on Drug-Dosing in Oncology: From ‘More Is Better’ to ‘Less Can Be More’

In a perspective article published in The New England Journal of Medicine entitled “The Drug-Dosing Conundrum in Oncology—When Less Is More,”...

 

 

 

 

 

Hematologic Malignancies
Lymphoma

Final Analysis of iNNOVATE: Addition of Ibrutinib to Rituximab for Waldenström’s Macroglobulinemia

As reported in the Journal of Clinical Oncology by Buske et al, the final analysis of the pivotal phase III iNNOVATE trial...

 

 

 

 

Head and Neck Cancer

Abiraterone for Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer

In an Italian single-institution phase II trial reported in the Journal of Clinical Oncology, Locati et al found that abiraterone acetate...

 

 


Advertisement
Lung Cancer
Genomics/Genetics

Second-Line Sotorasib Plus Afatinib for KRAS–Mutant NSCLC

The combination of the KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients...

 

 

 

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement



Sponsored Content


Issues in Oncology

Joann G. Elmore, MD, MPH, on Cancer Diagnosis: When Pathologists Disagree, Artificial Intelligence May Help

Lymphoma
Immunotherapy

Axicabtagene Ciloleucel Demonstrates Improvement Across Multiple Endpoints in Relapsed or Refractory Follicular Lymphoma

In the treatment of relapsed/refractory follicular lymphoma, a comparison of data from the ZUMA-5 trial with those of the external control cohort of the SCHOLAR-5 trial showed substantial improvement in all clinical endpoints with axicabtagene ciloleucel. John G. Gribben, DSc, FRCP, FRCPath,...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Solid Tumors
Gastrointestinal Cancer
Genomics/Genetics

Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib

Colorectal Cancer
Global Cancer Care

Colorectal Cancer Incidence and Mortality in European Countries

In a European population-based study reported in The Lancet Oncology, Cardoso et al found that colorectal cancer incidence and mortality declined more in European countries with long-standing colonoscopy or fecal test screening programs since the year 2000 compared to countries with more recently...

Hematologic Malignancies
Symptom Management

Third-Party BK Virus–Specific Cytotoxic T-Lymphocyte Therapy for BK Virus–Associated Hemorrhagic Cystitis After Stem Cell Transplant

In a single-institution phase II trial reported in the Journal of Clinical Oncology, Olson et al found that high rates of response were achieved with third-party BK virus–specific cytotoxic T-lymphocyte therapy (BKV-CTL) in patients with BK virus–associated hemorrhagic cystitis after allogeneic...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Solid Tumors
Immunotherapy

Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care

Kidney Cancer
Immunotherapy

No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...